OncoGenex Pharmaceuticals Inc (OGXI) Sees Significant Decline in Short Interest
OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) saw a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 760,164 shares, a decline of 2.7% from the April 28th total of 781,243 shares. Based on an average daily volume of 136,735 shares, the days-to-cover ratio is currently 5.6 days.
Shares of OncoGenex Pharmaceuticals (OGXI) opened at 0.36 on Friday. OncoGenex Pharmaceuticals has a one year low of $0.33 and a one year high of $1.32. The company’s 50 day moving average is $0.37 and its 200 day moving average is $0.48. The company’s market capitalization is $10.83 million.
OncoGenex Pharmaceuticals (NASDAQ:OGXI) last posted its quarterly earnings data on Monday, May 15th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.18. OncoGenex Pharmaceuticals had a negative return on equity of 50.34% and a negative net margin of 94.64%. Equities research analysts predict that OncoGenex Pharmaceuticals will post ($0.78) earnings per share for the current year.
A hedge fund recently raised its stake in OncoGenex Pharmaceuticals stock. Renaissance Technologies LLC increased its position in shares of OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) by 13.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,034,500 shares of the biopharmaceutical company’s stock after buying an additional 126,400 shares during the period. Renaissance Technologies LLC owned about 3.45% of OncoGenex Pharmaceuticals worth $517,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 18.54% of the company’s stock.
OncoGenex Pharmaceuticals Company Profile
OncoGenex Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.
Receive News & Ratings for OncoGenex Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.